Treatment
Azacitidine clinical trials
We’re tracking 179 recruiting studies that include Azacitidine, each written for real people, not researchers, below.
Recruiting studies
- NCT06279572Recruiting
Immune study of azacitidine and venetoclax in first AML treatment
This study looks at the immune system of adults with newly diagnosed AML who receive their first treatment of azacitidine and venetoclax. Researchers want to understand how this chemotherapy affects your immune cells.
Scottsdale, ArizonaAges 18 years+ - NCT06316960RecruitingPhase 2
Avapritinib for children with relapsed or resistant CBF-AML and KIT mutation
This trial tests a targeted drug called avapritinib in children and teens with a specific type of leukemia (CBF-AML) that has a KIT gene change and has come back or not responded to treatment. The goal is to see if avapritinib is safe and effective for these patients.
Hefei, AnhuiAges Up to 18 years - NCT06379360RecruitingPhase 2
Maintenance therapy for favorable-risk AML patients
This trial tests whether a maintenance treatment with a hypomethylating agent can help keep favorable-risk acute myeloid leukemia (AML) patients in remission after they have completed initial therapy. It is designed for patients who have achieved negative minimal residual disease (MRD) and have not received a stem cell transplant.
Suzhou, JiangsuAges 16 years+ - NCT06429098RecruitingPhase 2
Gentler drug combo for CBFB::MYH11 leukemia
This trial is testing a new combination of medicines (venetoclax plus other drugs, without strong chemotherapy) for people recently diagnosed with a specific genetic subtype of acute myeloid leukemia (CBFB::MYH11 positive). It aims to see if this gentler approach works well for patients who may not tolerate intensive chemo.
Suzhou, JiangsuAges 18 years+ - NCT06429449RecruitingPhase 1
Mitoxantrone for venetoclax-resistant AML
This trial tests a re-purposed drug, mitoxantrone, for people whose AML has not responded to or has come back after standard frontline treatment. The goal is to see if this older drug can help overcome resistance to venetoclax.
Aurora, ColoradoAges 18–80 - NCT06451861RecruitingPhase 2
Testing a new drug combo for newly diagnosed AML
This trial tests a new combination of drugs (ABC-14) against the standard treatment for adults newly diagnosed with acute myeloid leukemia (AML) who haven't had intensive treatment yet. The goal is to see if the new combo works better and is safe.
Dongguan, GuangdongAges 18 years+ - NCT06511882RecruitingPhase 2
Stopping AML treatment after reaching remission with no detectable disease
This trial tests whether it is safe to stop taking a type of chemotherapy (azacitidine or decitabine) combined with venetoclax if you have acute myeloid leukemia (AML) and have achieved a remission with no trace of leukemia cells. If you have been on this treatment for less than a year and are not eligible for a stem cell transplant, you may be able to stop therapy and be monitored closely.
Tampa, FloridaAges 18 years+ - NCT06532058RecruitingPhase 2
Study of a new drug for relapsed or hard-to-treat acute myeloid leukemia
This trial tests an experimental drug called QHRD107 combined with other medicines for people whose acute myeloid leukemia (AML) has come back or not responded to standard treatments. The goal is to see if the new combination is safe and helps control the leukemia.
Zhengzhou, HenanAges 18 years+ - NCT06532552RecruitingPhase 2
Comparing four drug combinations for older or unfit AML patients
This trial compares four different combinations of targeted therapy and chemotherapy for people with newly diagnosed AML who cannot have standard intensive chemo. The goal is to see which combination works best safely.
Suzhou, JiangsuAges 18 years+ - NCT06550713RecruitingPhase 1
Testing TQB3455 tablets for blood cancers with IDH2 mutation
This trial tests a new tablet, TQB3455, for people with certain blood cancers (MDS or AML) that have an IDH2 mutation. The goal is to see if the drug can help when other treatments haven't worked or aren't possible.
Beijing, Beijing MunicipalityAges 18 years+ - NCT04588922RecruitingPhase 1/Phase 2
Study drug SLS009 for high-risk leukemia in adults and teens
This early-phase study tests SLS009 (also called GFH009), a targeted medicine, to treat certain blood cancers—especially high-risk or difficult-to-treat AML. It’s designed to see how the drug works, how safe it is, and what dose may be best for you.
Birmingham, AlabamaAges 12 years+ - NCT06634394RecruitingPhase 1
Study of APVO436 for untreated AML patients
This trial tests a new drug called APVO436 for people with a type of acute myeloid leukemia (AML) that has not been treated before. It is for those who cannot receive strong standard chemotherapy due to age, health problems, or organ function issues.
Denver, ColoradoAges 18 years+ - NCT06635681RecruitingPhase 2
Venetoclax plus intensive chemo for AML subtypes
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
Tianjin, Tianjin MunicipalityAges 14–60 - NCT06686108RecruitingPhase 2
Medication combo to prevent lymphoma relapse after transplant
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
ShanghaiAges 14–55 - NCT06737523RecruitingPhase 1
A new combination therapy for relapsed or refractory AML
This trial tests a three-drug combination for patients whose AML has returned or not responded to prior treatment. It aims to see if adding a new drug (Chiglitazar) to standard treatments (Venetoclax and Azacitidine) can help control the leukemia.
Xiamen, FujianAges 18 years+ - NCT06741722RecruitingPhase 2
Study of mitoxantrone liposome combo for relapsed or refractory AML
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
BeijingAges 18–75 - NCT07000617RecruitingPhase 2
A study of drugs plus radiation for early-stage NK/T-cell lymphoma
This trial tests a combination of the drugs dexamethasone, azacitidine, pegaspargase, and tislelizumab along with radiation therapy for people with stage I or II extranodal NK/T-cell lymphoma. The goal is to see if this treatment works well and is safe for patients who have not yet received treatment.
BeijingAges 18 years+ - NCT07007949RecruitingPhase 2
New drug combo for adult AML with IDH1 mutation
This trial tests a combination of three drugs (ivosidenib, venetoclax, and azacitidine) for adults who have acute myeloid leukemia with a specific IDH1 gene change and have not been treated for AML before. The goal is to find a better first treatment option.
Suzhou, JiangsuAges 18 years+ - NCT07012447RecruitingPhase 2
Venetoclax with azacytidine for newly diagnosed T-cell leukemia
This trial tests a combination of venetoclax and azacytidine for people with certain types of T-cell acute lymphoblastic leukemia (T-ALL) that haven't been treated yet. It focuses on cases with specific genetic changes and aims to see if this drug pair can help control the disease.
Suzhou, JiangsuAges 14 years+ - NCT07018752RecruitingPhase 1/Phase 2
Testing new drug combos for relapsed T-cell lymphoma
This trial is testing several new drug combinations for people with peripheral T-cell lymphoma that has come back or not responded to treatment. It aims to find new options that may work better.
CaenAges 18 years+ - NCT07071155RecruitingEarly Phase 1
Momelotinib with a hypomethylating agent for certain blood cancers
This trial tests a combination of two drugs, momelotinib and a hypomethylating agent, for people with certain slow-growing blood cancers. If you have a diagnosis like chronic myelomonocytic leukemia or chronic neutrophilic leukemia and have an enlarged spleen, this study might be exploring a new treatment option for you.
Baltimore, MarylandAges 18–100 - NCT07075016RecruitingPhase 3
IDH1 mutation targeted therapy for untreated AML
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
FeldkirchAges 18 years+ - NCT07078591RecruitingPhase 2
Venetoclax with mini transplant for new AML
This trial tests combining the medicine Venetoclax with a mini stem-cell transplant from a partially matched relative for people with newly diagnosed acute myeloid leukemia (AML). It may help control the leukemia while reducing transplant side effects.
BeijingAges 18 years+ - NCT07132684RecruitingPhase 3
Comparing two chemotherapy plans for older AML patients
This trial compares two different combinations of chemotherapy drugs for older adults (ages 55-75) with newly diagnosed acute myeloid leukemia (AML) who are otherwise healthy enough to tolerate intensive treatment. The goal is to see which combination is more effective and has fewer side effects.
TianjinAges 55–75
Common questions
- Are there clinical trials studying Azacitidine?
- Yes. Clin2 currently lists 179 recruiting studies that include Azacitidine, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Azacitidine trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Azacitidine an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Azacitidine or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.